Isavuconazole
Cresemba (isavuconazole) is a small molecule pharmaceutical. Isavuconazole was first approved as Cresemba on 2015-10-15. It is used to treat aspergillosis and mucormycosis in the USA. It has been approved in Europe to treat aspergillosis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cresemba | New Drug Application | 2023-12-08 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| aspergillosis | EFO_0007157 | D001228 | B44 |
| mucormycosis | EFO_0007380 | D009091 | B46.5 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
58 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mycoses | D009181 | — | B35-B49 | — | — | 4 | 1 | 3 | 8 |
| Invasive fungal infections | D000072742 | — | — | — | — | 2 | 1 | 2 | 5 |
| Invasive hydatidiform mole | D002820 | — | D39.2 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aspergillosis | D001228 | EFO_0007157 | B44 | — | 2 | 4 | — | 4 | 10 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 4 | 6 | 1 | — | — | 6 |
| Leukemia | D007938 | — | C95 | 3 | 5 | 1 | — | — | 5 |
| Myeloid leukemia | D007951 | — | C92 | 3 | 5 | 1 | — | — | 5 |
| Invasive pulmonary aspergillosis | D055744 | — | B44.0 | — | 2 | 1 | — | 2 | 5 |
| Infections | D007239 | EFO_0000544 | — | — | — | 1 | — | 2 | 3 |
| Pulmonary aspergillosis | D055732 | EFO_1001834 | — | — | 1 | 1 | — | — | 2 |
| Candidemia | D058387 | EFO_1001282 | — | — | — | 1 | — | — | 1 |
| Invasive candidiasis | D058365 | EFO_1001283 | B37 | — | — | 1 | — | — | 1 |
| Candidiasis | D002177 | — | B37 | — | — | 1 | — | — | 1 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mucormycosis | D009091 | EFO_0007380 | B46.5 | — | 2 | — | — | 4 | 6 |
| Zygomycosis | D020096 | — | B46 | — | 2 | — | — | 4 | 6 |
| Lymphoma | D008223 | — | C85.9 | 1 | 2 | — | — | — | 3 |
| Central nervous system neoplasms | D016543 | — | — | — | 2 | — | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | 1 | 1 | — | — | — | 2 |
| Neoplasms | D009369 | — | C80 | 2 | 1 | — | — | — | 2 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 2 | 2 | — | — | — | 2 |
| B-cell lymphoma | D016393 | — | — | — | 1 | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | — | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | — | 1 | — | — | — | 1 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 25 | — | — | — | — | 25 |
| Pharmacokinetics | D010599 | — | — | 3 | — | — | — | 1 | 4 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Communicable diseases | D003141 | — | — | — | — | — | — | 1 | 1 |
| Bacterial infections | D001424 | — | A49 | — | — | — | — | 1 | 1 |
| Neuroaspergillosis | D020953 | EFO_0007393 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Isavuconazole |
| INN | isavuconazole |
| Description | Isavuconazole is a 1,3-thiazole that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,5-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively. It is an antifungal drug used for the treatment of invasive aspergillosis and invasive mucormycosis. It has a role as an ergosterol biosynthesis inhibitor, an EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor and an orphan drug. It is a member of 1,3-thiazoles, a nitrile, a difluorobenzene, a tertiary alcohol, a triazole antifungal drug and a conazole antifungal drug. |
| Classification | Small molecule |
| Drug class | systemic antifungals (miconazole type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@](O)(Cn1cncn1)c1cc(F)ccc1F |
Identifiers
| PDB | — |
| CAS-ID | 241479-67-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL409153 |
| ChEBI ID | 85979 |
| PubChem CID | 6918485 |
| DrugBank | DB11633 |
| UNII ID | 60UTO373KE (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Cresemba – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,692 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,741 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use